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Introduction: Intravitreal injection of ranibizumab has become one of the most commonly 
performed ophthalmic procedures. It is timely to conduct an evaluation of the injection   procedure 
from the patient’s perspective so as to determine ways to improve patient experience. The   purpose 
of this study was to quantitatively describe patients’ experiences of the different stages of the 
intravitreal injection procedure and provide suggestions for improvement.
Method: Following intravitreal injection, patients were administered a questionnaire to score 
the distress felt for each of ten parts of the whole injection process from the initial waiting to 
the final instillation of topical antibiotic at the end. A score of higher than 4 was regarded as 
significantly unpleasant. The proportion of scores above 4 for each step was used to evaluate 
the relative distress experienced by patients for the different parts of the procedure.
Results: A total of 42 patients were surveyed. The step with the highest percentage of patients 
scoring more than 4 was the injection step (19%). However, cumulatively, the steps relating 
to the application of the drape, the speculum, and the removal of drape accounted for 53% of 
scores greater than 4.
Conclusion: There is considerable variation in how patients tolerate different stages of the 
injection procedure. The needle entry was the most unpleasant step followed by the draping steps 
cumulatively. Use of subconjunctival anesthesia, a perforated drape, and alternative lid exclusion 
devices may help to improve the patient’s tolerability of the procedure and experience.
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Introduction
Intravitreal injection of ranibizumab is now an established treatment modality in wet 
age-related macular degeneration (AMD) and has become one of the most   commonly 
performed ophthalmic surgical procedures in our clinical practice. In a hospital 
department providing services for a population of about 500,000 it is estimated that 
about 50–100 injection procedures are performed every week.1 It is also a procedure 
that is experienced repeatedly by any individual patient who is being treated for wet 
AMD. Although the frequency of injections varies widely from patient to patient, on 
average about ten injections per eye are required over a 2-year period.2
It is also anticipated that an increasing number of patients, especially those of a 
younger age group, will require intravitreal injections as the indications for intravitreal 
ranibizumab extend to include other conditions such as diabetic macular edema and 
retinal vein occlusions. It is timely, therefore, to conduct an evaluation of the intravitreal 
injection procedure from the perspective of the patient to learn about the experiences 
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of the patient undergoing repeated injections and also to 
determine whether there are ways to improve the technique.
The objective of this study was to quantitatively describe 
the patients’ experiences by determining their opinion on 
separate and distinct steps of the whole injection process.
Methods
Patients attending for routine injection visits as part of a 
two-stop wet AMD treatment program were intended for 
the study. Prior to listing for intravitreal ranibizumab, 
patients were fully counseled. This included details of the 
procedure including what to expect during and following 
the procedure. During the surgical visits, patients typically 
followed a fixed pathway of procedures, which included: 
logMAR visual acuity measurement; and instillation of 
topical proxymethocaine 0.5%, tropicamide 1%, and 
chloramphenicol 0.5% (Chauvin Pharmaceuticals, Surrey, 
UK) before entering a clean room for the injection procedure. 
A questionnaire was designed to capture the detail of 
patients’ experiences of the injection procedure by dividing 
the process into ten discreet steps, each of which was scored 
by patients using a visual analogue scale. The ten discreet 
steps included: (1) waiting for injection, (2) instillation of 
drops, (3) application of drape, (4) cutting of drape, (5) 
insertion of speculum, (6) povidone flush, (7) needle entry, 
(8) irrigation, (9) speculum and drape removal, and (10) 
instillation of antibiotics. In the pilot study, patients did not 
comment on post procedure symptoms (such as floaters) 
being of concern, and therefore these were not included in 
the questionnaire.
Patients attending for a routine injection visit and who 
had had five or more injections previously were invited to 
participate. Patients who had had less than five previous 
injections were not recruited, as in our experience they tended 
to be more anxious and their recall post procedure was less 
accurate. Patients were given explanatory information about 
the study prior to entering the clean room. Trained retinal 
specialists and experienced ophthalmologists performed all 
injections. A nurse immediately at the end of the injection 
procedure administered the questionnaire. Patients were 
asked to rank their experience for each of the ten steps on a 
visual analogue scale of 1–10, with 1 being the most bearable 
and 10 most unpleasant. Comments from patients who 
expressed specific concerns were noted. The results of the 
questionnaire were tabulated and analyzed with descriptive 
statistics. An arbitrary discomfort cutoff score of 4 or more 
was used as significant (significant discomfort).
Results
Forty-two (14 female, 28 male) patients completed question-
naires. The mean age of the cohort was 76 years. At the time 
of completing the questionnaire the mean number of previous 
injections experienced by the participants was 7.80.
The distributions of the mean and range of scores for 
each step are shown in Table 1. In terms of proportions of 
patients scoring each item as significantly uncomfortable 
or unpleasant (ie, .4), the most unpopular steps included 
waiting for injection, application of drape, insertion of 
speculum, and also the needle entry itself. The proportions 
of patients scoring each step as significantly unpleasant are 
shown in Figure 1. When the steps associated with the whole 
draping process were grouped together, they accounted for 
53% of the high scorers (Figure 2). Following the “draping 
process,” the injection itself accounted for 19%, and 
waiting in the waiting area accounted for 13% of patient 
discomfort.
In terms of comments, patients frequently repeated four 
comments. These were, despite having multiple injections: 
the experience is not any easier; fear as scissors (to cut the 
drape) pass over the eye, fear when seeing the injection 
needle coming, and discomfort when the drape is placed on 
and taken off.
Discussion
The intravitreal injection procedure is fairly standardized in 
the UK, with guidelines provided by the Royal College of 
Ophthalmologists that aim to ensure that the procedure is safe 
and sterile.3 Other publications from outside the UK have 
also provided guidance on best practice for the intravitreal 
injection procedure.4,5
Patients with less than five previous injections were 
not recruited due to greater anxiety levels and poorer 
Table 1 Mean and range of scores for each step of the intravitreal 
injection procedure
Step Mean score out of ten   
(range)
Waiting for injection 2.3 (1–6)
Drop instillation 1.4 (1–5)
Drape application 3.0 (1–10)
Cutting of drape 2.6 (1–10)
Insertion of speculum 2.7 (1–10)
Povidone flush 1.8 (1–10)
Needle entry 3.2 (1–10)
Water irrigation 1.3 (1–4)
Drape removal 1.6 (1–6)
Antibiotics instillation 1.6 (1–10)
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post-  procedure recall of their experience. Chua et al 
(2009)6 demonstrated in a group of treatment-naïve (34%) 
and previously treated (66%) patients that the anticipated 
discomfort was 31% higher compared with the actual discom-
fort experienced during the procedure. Chua et al did not 
perform subgroup analysis but, in our experience of over 
5000 intravitreal injections, patients who are treatment naïve 
or have had less than five injections tend to be more anxious, 
with poorer recall.
In this study of the patient experience of the intravitreal 
injection procedure, there was a wide variation in the scores 
given by patients rating the discomfort of the various steps. 
These findings were supported qualitatively by the patients’ 
comments.
There have been several publications reviewing patients’ 
visual experiences during intravitreal injections,7 cataract 
surgery,8–10 and during vitreoretinal surgery.11 The evaluation 
of patients’ experiences during procedures under local 
anesthesia can help towards design of more patient-friendly 
techniques and procedures. This approach has been shown 
to result in patient-orientated approaches, especially in eye 
surgery when emotive factors are naturally more relevant to 
patients.7–11
The findings in this study can potentially help us improve 
patients’ experiences around the repeated exposures to 
intravitreal injections that they have to endure. Although it 
is widely acceptable for injections to be carried out under 
topical anesthesia, it is clear that a significant proportion of 
patients experience discomfort and express this as a variety 
of levels in a visual analogue scale. This single factor could 
be safely addressed by the use of a small quantity of sub-
conjunctival anesthetic. Since the completion of this study, 
we have offered this option, especially to those patients who 
repeatedly feel a high level of discomfort; to date we have 
received good feedback.
The placement of a drape and insertion of speculum is 
necessary to exclude the lid margins and lashes from the 
surgical field and to prevent direct touch of the needle shaft 
with the lid margin or lashes. This is a very important aspect 
of the aseptic procedure and cannot be easily abandoned. An 
alternative to the standard ophthalmic drape is a pre-perforated 
drape, which obviates the need to cut the drape with scissors. 
Alternatively, recent developments of intravitreal injection 
aids which exclude the lids without a need for a drape and 
speculum, such as the Veni Vedi Invitria® device (FCI Surgical 
Devices, Paris, France)12 may help. However, the substitution 
of the conventional speculum and drape with such a device 
represents a major change in technique, which warrants future 
studies or prospective surveillance for safety.
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Figure 1 Distribution of patients’ responses of significant discomfort (score $ 4) for each step of the intravitreal injection procedure.
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Figure 2 Distribution of patients’ responses of significant discomfort (score $ 4) 
with the “draping process,” grouped as a whole. The draping process accounts for 
53% of the total number of significant discomfort responses.
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This study has highlighted some of the issues   surrounding 
the tolerability of repeated injections for patients. Although 
these effects are transient and do not lead to any permanent 
clinical morbidity, they occur very frequently in a large 
number of patients and also frequently for individuals 
undergoing injections repeatedly. Implementation of steps to 
improve unpleasant aspects, such as sensation of needle entry 
and also the draping and speculum application procedures, 
where possible, should enable us to improve the patients’ 
experiences considerably.
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